# Genmab: Phase 2 study terminated, 125 enrolled (Non Small Cell Lung Cancer Metastatic)

**Score:** 70/100

| Field | Value |
|---|---|
| Sponsor | Genmab |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer |
| NCT ID | NCT05117242 |
| Phase | Phase 2 |
| Status | terminated |
| Conditions | Non Small Cell Lung Cancer Metastatic |
| Intervention types | biological |
| Target enrollment | 125 |
| Site countries | United States, France, Germany, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom |
| Posted | 2021-11-11 |
| Planned start | 2021-10-27 |
| Event | Terminated |
| Event date | 2026-08-31 |
| Last update posted | 2026-09-21 |

## Why this score
- Industry sponsor (buys outsourced services).
- Stopped early: budget and sites freed up.
- Phase 2: multi-site, larger budget.
- 125 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05117242). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.